Mode
Text Size
Log in / Sign up
Phase 2 N=15 Randomized Triple-blind Treatment

A Randomized Trial of CT Fluoroscopy-guided Targeted Autologous Blood and Fibrin Glue Patching for Treatment

Cerebrospinal Fluid Leaks

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Change in Median (Headache Impact Test-6) HIT-6 Score From Baseline — -12; -7 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
TISSEEL (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Duke University
Primary completion
Mar 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Median (Headache Impact Test-6) HIT-6 Score From Baseline
-12; -7
SECONDARY
Change in Median HIT-6 Score From Baseline
-5.5; -7; -4.5; -12
SECONDARY
Reduction in Median Migraine Disability Assessment (MIDAS) Score From Baseline
-25; 16; -62.5; -40; -87; -53
SECONDARY
Change in Median NRS Score From Baseline
-0.5; -1; -2.5; 0; -1.5; -2
SECONDARY
Change in Median EQ-5D (European Quality of Life-5 Dimensions) Score From Baseline
0.1; 0.1; 0; 0.1; 0; 0.2
SECONDARY
Change in Median WPAI (Work Productivity and Activity Impairment) Score From Baseline
1.3; -0.3; -13.8; -2.3; -9; -28.5
SECONDARY
Change in PGIC (Patient Global Impression of Change) Score From Baseline
3.5; 2; 4; 3; 4.5; 6

Summary

The goal of this randomized controlled trial (RCT) is to compare the efficacy of CT fluoroscopy-guided targeted epidural patching for treatment of imaging-confirmed spinal CSF leaks to that of a simulated procedure without patching material in patients with spontaneous intracranial hypotension.

Eligibility Criteria

Inclusion Criteria

  • Adult patients meeting International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria for a diagnosis of SIH (Table 1) who have had a contrast-enhanced brain MRI and a myelogram confirming the presence of a CSF leak will be recruited from the Duke Radiology spine intervention clinic [25]

Exclusion Criteria

  • recent (i.e., < 2 weeks) blood patch
  • contraindication or inability to undergo the procedure
  • inability to provide informed consent
  • expected inability to complete follow-up assessment
  • a contraindication to receiving contrast material (precluding an epidurogram)
  • contraindication to receiving fibrin glue (i.e., allergy).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03276975). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search